AMUNIX
Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics. The company is focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. By delivering breakthrough therapies that can safely harness the immune system, it aims to conquer cancer and save lives. Its pipeline products are based on its proprietary XTEN half-life extension, XDC drug-conjugate d... elivery, and ProTIA pro-drug, bispecific T cell engager platform and have ongoing collaborations with biopharma corporations harnessing these delivery technologies over a wide range of therapeutic areas, delivering improved pharmaceutical technologies. Amunix was founded in 2006 and is headquartered in Mountain View, California.
AMUNIX
Social Links:
Industry:
Biotechnology Medical Therapeutics
Founded:
2006-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.amunix.com
Total Employee:
11+
Status:
Active
Contact:
650-428-1800
Email Addresses:
[email protected]
Total Funding:
190 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Google Tag Manager Google Analytics Google Maps Content Delivery Network HSTS IPv6 Apache US Privacy User Signal Mechanism
Similar Organizations
Ambys Medicines
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies.
aTyr Pharma
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics.
Codiak Biosciences
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.
GigaGen
GigaGen specialized in the early discovery and development of recombinant biotherapeutic medicines.
Gossamer Bio
Gossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series B - Amunix
Clough Capital Partners
Clough Capital Partners investment in Series B - Amunix
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series B - Amunix
Polaris Partners
Polaris Partners investment in Series B - Amunix
Franklin Templeton
Franklin Templeton investment in Series B - Amunix
CaaS Capital Management
CaaS Capital Management investment in Series B - Amunix
BlackRock
BlackRock investment in Series B - Amunix
ArrowMark Partners
ArrowMark Partners investment in Series B - Amunix
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Amunix
Longitude Capital
Longitude Capital investment in Series B - Amunix
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2013-10-08 | Versartis | Amunix investment in Series D - Versartis | 20 M USD |
Official Site Inspections
http://www.amunix.com Semrush global rank: 10.33 M Semrush visits lastest month: 234
Unable to get host informations!!!
More informations about "Amunix"
Amunix - Crunchbase Company Profile & Funding
Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics. The company is focused on developing prodrugs to bring the promise of potent immune …See details»
Sanofi to Acquire Amunix for Oncology Innovation | Sanofi
Dec 21, 2021 XTEN, XPAT, XPAC and PRO-XTEN are trademarks in the name of Amunix. About Amunix. Amunix Pharmaceuticals is an immuno-oncology company focused on …See details»
Sanofi completes acquisition of Amunix
Feb 8, 2013 The acquisition also provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next generation Conditionally Activated Biologics. The technology …See details»
Sanofi completes acquisition of Amunix - PharmiWeb.com
Paris, February 8, 2022.Sanofi announced today the completion of its acquisition of Amunix Pharmaceuticals, Inc, adding a promising pipeline of T-cell engagers and cytokine …See details»
Sanofi Acquiring Amunix Pharmaceuticals for $1B - Nasdaq
Dec 22, 2021 Sanofi (SNYNF) has reached an agreement to acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company, for $1 billion. The company is also to pay up to $225 …See details»
Sanofi to acquire Amunix immuno-oncology pipeline with next …
Dec 21, 2021 Amunix’s pipeline, which includes lead candidate, AMX-818, a masked HER2-directed TCE, offers a strong strategic fit with Sanofi’s focus on developing potentially …See details»
Sanofi to acquire immuno-oncology firm Amunix for …
Dec 22, 2021 Sanofi has signed an agreement for the acquisition of immuno-oncology firm Amunix Pharmaceuticals for nearly $1bn in upfront payment. Amunix designs and develops masked T cell engagers (TCE) and cytokines to …See details»
Sanofi (SNY) to Acquire Amunix, Boost Immuno …
Dec 21, 2021 Sanofi SNY announced that it has entered into an agreement to acquire privately-held, immuno-oncology company, Amunix Pharmaceuticals, for an upfront payment of approximately $1 billion.. The ...See details»
Sanofi completes acquisition of Amunix
Feb 8, 2022 Sanofi completes acquisition of Amunix Paris, February 8, 2022. Sanofi announced today the completion of its acquisition of Amunix Pharmaceuticals, Inc, adding a promising …See details»
Amunix Raises $117 Million Series B Financing to Fund ... - Yahoo …
Mar 4, 2021 Amunix’s proprietary masking technology has been clinically validated to extend drug half-life with limited immunogenicity. The company’s pipeline includes AMX-818, an …See details»
Sanofi buys US immuno-oncology biotech Amunix for $1 billion
Oct 9, 2024 Sanofi has bolstered its immuno-oncology pipeline with a $1 billion agreement to acquire Amunix Pharma of the US – its fourth bolt-on deal of 2021. South San Francisco …See details»
Sanofi to buy immuno-oncology company Amunix for $1 billion
Dec 21, 2021 Shares of Sanofi gained 0.8% in trading on Tuesday after the company announced plans to buy Amunix Pharmaceuticals Inc., a privately held immuno-oncology …See details»
Sanofi to acquire Amunix immuno-oncology pipeline with next
Dec 21, 2021 Sanofi to acquire Amunix immun o- oncology pipeline with next generation C onditionally A ctivated B iologics. PARIS– December 21, 2021– Sanofi announced today that it …See details»
Sanofi to acquire immuno-oncology firm Amunix - Chemical
Dec 30, 2021 Amunix was founded over 15 years ago but didn’t raise its first major funding round—a $73 million series A—until 2020. It brought in another $117 million in March 2021.See details»
Sanofi to acquire Amunix immuno-oncology pipeline with next …
Dec 21, 2021 with cancer. Amunix’s pipeline, which includes lead candidate, AMX-818, a masked HER2-directed TCE, offers a strong strategic fit with Sanofi’s focus on developing …See details»
Sanofi to acquire Amunix immuno-oncology pipeline
Dec 21, 2021 Paris-based Sanofi is buying South San Francisco’s Amunix Pharmaceuticals in a deal topping $1.225 billion.. Amunix focuses on immuno-oncology with a proprietary XEN and …See details»
Sanofi to Buy Amunix for Up to $1.2 Billion for Cancer Drugs
Dec 21, 2021 Sanofi agreed to buy privately held Amunix Pharmaceuticals Inc. for as much as $1.2 billion to increase its pipeline of promising cancer medicines.See details»
Sanofi to acquire Amunix immuno-oncology pipeline with next …
Dec 21, 2021 XTEN, XPAT, XPAC and PRO-XTEN are trademarks in the name of Amunix. About Amunix . Amunix Pharmaceuticals is an immuno-oncology company focused on …See details»
Amunix scores $117M to fuel T-cell engagers, cytokines for solid …
Mar 4, 2021 Amunix started out in 2006 and spent most of its life licensing technology to the likes of Biogen and Merck to extend the half-lives of their medicines. The application of the …See details»
Sanofi completes acquisition of Amunix - GlobeNewswire
Feb 8, 2022 Sanofi announced today the completion of its acquisition of Amunix Pharmaceuticals, Inc, adding a promising pipeline of T-cell engagers and cytokine therapies. …See details»